Search
MK-8666
go.drugbank.com/drugs/DB14937InvestigationalMK-8666 is under investigation in clinical trial NCT01971554 (Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of MK-8666 in Participants With Type 2 Diabetes Mellitus (MK-8666-003)).
Tolrestat
go.drugbank.com/drugs/DB02383ApprovedWithdrawnTolrestat (INN) (AY-27773) is an aldose reductase inhibitor which was approved for the control of certain diabetic complications. … While it was approved for marketed in several countries, it failed a Phase III trial in the U.S. due to toxicity and never received FDA approval.
Modafinil
go.drugbank.com/drugs/DB00745ApprovedInvestigationalModafinil is a stimulant drug marketed as a 'wakefulness promoting agent' and is one of the stimulants used in the treatment of narcolepsy. Narcolepsy is caused by dysfunction of a family of wakefulness-promoting and sleep-suppressing pe...
Categories: Psychostimulants, Agents Used for ADHD and NootropicsFX06
go.drugbank.com/drugs/DB05685InvestigationalFX06 has proven safe in acute and subchronic toxicological studies and recently entered clinical development. It is being developed by Fibrex Medical Inc.
CM4620
go.drugbank.com/drugs/DB16466InvestigationalCM4620 (Zegocractin), is under investigation in multiple clinical trials, including NCT04195347 (pancreatitis due to asparaginase), NCT03709342 (PK/PD study in acute pancreatitis), NCT03401190 and NCT04681066
Categories: Experimental Unapproved Treatments for COVID-19Veru-111
go.drugbank.com/drugs/DB16462InvestigationalVERU-111, an investigational drug intended for various therapeutic uses, was under investigation in clinical trials NCT04842747, NCT03752099, NCT04388826, NCT04844749, NCT05008510, and NCT05079360.
Categories: Experimental Unapproved Treatments for COVID-19Yttrium Y-90
go.drugbank.com/drugs/DB13076ApprovedInvestigationalYttrium 90 has been investigated for the treatment of Colon Cancer and Colorectal Cancer.
Momelotinib
go.drugbank.com/drugs/DB11763ApprovedInvestigationalMomelotinib is a Janus Kinase 1 (JAK1) and 2 (JAK2) inhibitor. It is a competitive inhibitor of JAK ATP binding. First approved by the FDA on September 15, 2023, momelotinib is used to treat myelofibrosis. Myelofibrosis (MF) is a group o...
Talazoparib
go.drugbank.com/drugs/DB11760ApprovedInvestigationalTalazoparib is an inhibitor of mammalian polyadenosine 5’-diphosphoribose polymerases (PARPs), enzymes responsible for regulating essential cellular functions, such as DNA transcription and DNA repair.
Mephentermine
go.drugbank.com/drugs/DB01365ApprovedWithdrawnIt is used to maintain blood pressure in hypotensive states, for example, following spinal anesthesia.